Ozone therapy could attenuate tubulointerstitial injury in adenine-induced CKD rats by mediating Nrf2 and NF-κB

Document Type : Original Article


Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China


Objective(s): This study aims to determine the effects of ozone therapy on restoring impaired Nrf2 activation to ameliorate chronic tubulointerstitial injury in rats with adenine-induced CKD.
Materials and Methods: Sprague–Dawley rats were fed with 0.75% adenine-containing diet to induce CKD and chronic tubulointerstitial injury. Ozone therapy was administered by rectal insufflation. After 4 weeks, serum and kidney samples were collected and analyzed. Renal function and systemic electrolyte level were detected. Pathological changes in kidney were assessed by hematoxylin–eosin staining and Masson trichrome staining. Nrf2 activation was detected by immunohistochemistry and Western blot analyses. The levels of SOD, CAT, GSH, PCO, and MDA were detected in the kidney. Immunohistochemistry, Western blot, and real-time PCR analyses were performed to evaluate the activation of the nuclear factor kappa B (NF-κB) P65 pathway and inflammation infiltration in the tubulointerstitium of the rats.
Results: Ozone therapy improved severe renal insufficiency and tubulointerstitial morphology injury as well as restored Nrf2 activation and inhibited the NF-κB pathway in rats with adenine-induced CKD. Ozone therapy also up-regulated anti-oxidation enzymes (SOD, CAT, and GSH) and down-regulated oxidation products (PCO and MDA), as well as inflammatory cytokines (IL-1β, IL-6, TNF-α, and ICAM-1) in the kidney.
Conclusion:These findings indicated that ozone therapy could attenuate tubulointerstitial injury in rats with adenine-induced CKD by mediating Nrf2 and NF-κB.


1. Lee SY, Kim SI, Choi ME. Therapeutic targets for treating fibrotic kidney diseases. Transl Res 2015; 165:512-530.
2. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382:260-272.
3. Remuzzi G, Benigni A, Finkelstein FO, Grunfeld J-P, Joly D, Katz I, et al. Kidney failure: aims for the next 10 years and barriers to success. Lancet 2013; 382:353-362.
4. Eckardt K-U, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013; 382:158-169.
5. Eardley KS, Zehnder D, Quinkler M, Lepenies J, Bates RL, Savage CO, et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int 2006; 69:1189-1197.
6. Hodgkins KS, Schnaper HW. Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr Nephrol 2012; 27:901-909.
7. Kim H, Vaziri N. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010; 298:662-671.
8. Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 2013;83:1029-1041.
9. Wakabayashi N, Slocum S, Skoko J, Shin S, Kensler T. When NRF2 Talks, Who's Listening? Antioxid Redox Signal 2010; 13:1649-1663.
10. Jiang T, Tian F, Zheng H, Whitman SA, Lin Y, Zhang Z, et al. Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-kappaB-mediated inflammatory response. Kidney Int 2014; 85:333-343.
11. Bocci V. Ozone as Janus: this controversial gas can be either toxic or medically useful. Mediators Inflamm 2004; 13:3-11.
12. Di Filippo C, Marfella R, Capodanno P, Ferraraccio F, Coppola L, Luongo M, et al. Acute oxygen-ozone administration to rats protects the heart from ischemia reperfusion infarct. Inflamm Res 2008; 57:445-449.
13. El-Sawalhi M, Darwish H, Mausouf M, Shaheen A. Modulation of age-related changes in oxidative stress markers and energy status in the rat heart and hippocampus: a significant role for ozone therapy. Cell Biochem Funct 2013; 31:518-525.
14. Paoloni M, Di Sante L, Cacchio A, Apuzzo D, Marotta S, Razzano M, et al. Intramuscular oxygen-ozone therapy in the treatment of acute back pain with lumbar disc herniation: a multicenter, randomized, double-blind, clinical trial of active and simulated lumbar paravertebral injection. Spine (Phila Pa 1976) 2009; 34:1337-1344.
15. Zhang J, Guan M, Xie C, Luo X, Zhang Q, Xue Y. Increased growth factors play a role in wound healing promoted by noninvasive oxygen-ozone therapy in diabetic patients with foot ulcers. Oxid Med Cell Longev 2014; 2014:273475.
16. Pecorelli A, Bocci V, Acquaviva A, Belmonte G, Gardi C, Virgili F, et al. NRF2 activation is involved in ozonated human serum upregulation of HO-1 in endothelial cells. Toxicol Appl Pharmacol 2013; 267:30-40.
17. Re L, Martínez-Sánchez G, Bordicchia M, Malcangi G, Pocognoli A, Morales-Segura M, et al. Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway in vivo? A preliminary result. Eur J Pharmacol 2014; 742:158-162.
18. Yokozawa T, Zheng PD, Oura H, FK. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986; 44:230-234.
19. Yokozawa T, Oura H, Okada T. Metabolic effects of dietary purine in rats. J Nutr Sci Vitaminol (Tokyo) 1982; 28:519-526.
20. Leon Fernandez OS, Ajamieh HH, Berlanga J, Menendez S, Viebahn-Hansler R, Re L, et al. Ozone oxidative preconditioning is mediated by A1 adenosine receptors in a rat model of liver ischemia/ reperfusion. Transpl Int 2008; 21:39-48.
21. Borrego A, Zamora Z, González R, Romay C, Menéndez S, Hernández F, et al. Protection by ozone preconditioning is mediated by the antioxidant system in cisplatin-induced nephrotoxicity in rats. Mediators Inflamm 2004; 13:13-19.
22. Nicholas SB, Yuan J, Aminzadeh A, Norris KC, Crum A, Vaziri ND. Salutary effects of a novel oxidative stress modulator on adenine-induced chronic progressive tubulointerstitial nephropathy. Am J Transl Res 2012; 4:257-268.
23. Vaziri ND, Liu SM, Lau WL, Khazaeli M, Nazertehrani S, Farzaneh SH, et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One 2014; 9:e114881.
24. Aminzadeh MA, Nicholas SB, Norris KC, Vaziri ND. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol Dial Transplant 2013; 28:2038-2045.
25. Borra SK, Mahendra J, Gurumurthy P, Jayamathi, Iqbal SS, Mahendra L. Effect of curcumin against oxidation of biomolecules by hydroxyl radicals. J Clin Diagn Res 2014; 8:CC01-05.
26. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton) 2012; 17:311-321.
27. Dalle-Donne I, Rossi F, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2002; 329:23-38.
28. Shehata NI, Abd-Elgawad HM, Mawsouf MN, Shaheen AA. The potential role of ozone in ameliorating the age-related biochemical changes in male rat cerebral cortex. Biogerontology 2012; 13:565-581.
29. Koca K, Yurttas Y, Bilgic S, Cayci T, Topal T, Durusu M, et al. Effect of preconditioned hyperbaric oxygen and ozone on ischemia-reperfusion induced tourniquet in skeletal bone of rats. J Surg Res 2010; 164:e83-89.
30. Ekici S, Dogan Ekici AI, Ozturk G, Benli Aksungar F, Sinanoglu O, Turan G, et al. Comparison of melatonin and ozone in the prevention of reperfusion injury following unilateral testicular torsion in rats. Urology 2012; 80:899-906.
31. Re L, Martinez-Sanchez G, Bordicchia M, Malcangi G, Pocognoli A, Morales-Segura MA, et al. Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway in vivo? A preliminary result. Eur J Pharmacol 2014; 742:158-162.
32. Ichikawa I, Kiyama S, Yoshioka T. Renal antioxidant enzymes: their regulation and function. Kidney Int 1994; 45:1-9.
33. Vaillant JD, Fraga A, Diaz MT, Mallok A, Viebahn-Hansler R, Fahmy Z, et al. Ozone oxidative postconditioning ameliorates joint damage and decreases pro-inflammatory cytokine levels and oxidative stress in PG/PS-induced arthritis in rats. Eur J Pharmacol 2013; 714:318-324.
34. Chen H, Xing B, Liu X, Zhan B, Zhou J, Zhu H, et al. Ozone oxidative preconditioning inhibits inflammation and apoptosis in a rat model of renal ischemia/reperfusion injury. Eur J Pharmacol 2008; 581:306-314.
35. Wong ET, Tergaonkar V. Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2009; 116:451-465.
36. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3:17-26.
37. Chen Z, Liu X, Yu G, Chen H, Wang L, Wang Z, et al. Ozone therapy ameliorates tubulointerstitial inflammation by regulating TLR4 in adenine-induced CKD rats. Ren Fail 2016:1-9.
38. Pedruzzi LM, Stockler-Pinto MB, Leite M Jr, Mafra D. Nrf2-keap1 system versus NF-kappaB: the good and the evil in chronic kidney disease? Biochimie 2012; 94:2461-2466.
39. Buelna-Chontal M, Zazueta C. Redox activation of Nrf2 & NF-kappaB: a double end sword? Cell Signal 2013; 25:2548-2557.
40. Sun CC, Li SJ, Yang CL, Xue RL, Xi YY, Wang L, et al. Sulforaphane Attenuates Muscle Inflammation in Dystrophin-deficient mdx Mice via NF-E2-related Factor 2 (Nrf2)-mediated Inhibition of NF-kappaB Signaling Pathway. J Biol Chem 2015; 290:17784-17795.
41. Kim J, Woo J, Lyu JH, Song HH, Jeong HS, Ha KT, et al. Carthami Flos suppresses neutrophilic lung inflammation in mice, for which nuclear factor-erythroid 2-related factor-1 is required. Phytomedicine 2014; 21:470-478.